Interview with Cornelia Yzer , CEO, VFA
2007 was a turning point for the German Pharmaceutical Industry as the Healthcare Reform from 2007 took place and the Special SHI enhancement Act entered into force. Two years down…
Address: An der Wiek 7, 17493 Greifswald – Insel Riems,Germany
Tel: +49 38351 76-0
RIEMSER Arzneimittel AG is a company with tradition and a future.Following its demerger from the Friedrich-Loeffler-Institute Riems Island (FLI), RIEMSER Arzneimittel AG has, within a period of just a few years, evolved to become one of East Germany’s largest producers and developers of pharmaceutical products.RIEMSER has affiliated branches in such German Federal States such as Saarland, Baden-Württemberg, and Saxony as well as abroad. The company has more than 618 employees at various locations. In 2008, the group achieved sales of the order of 85,4 million euros. RIEMSER exports to more than 80 countries, including China, Russia and the U.S.A. Business transacted abroad will grow to more than 40 percent of total sales in fiscal 2009. The company prides itself on a well-diversified portfolio, which encompasses the areas human, veterinary, and dental. Its core competencies focus on oncology and dermatology as well as on dental products and anti-infectives, in veterinary, the emphasis is on animal vaccines.
2007 was a turning point for the German Pharmaceutical Industry as the Healthcare Reform from 2007 took place and the Special SHI enhancement Act entered into force. Two years down…
What role does the German Pharmaceutical Industry Association (BPI) play for the German pharmaceutical industry? BPI is the oldest industry association of the German pharmaceutical industry, dating back to 1951.…
Next year Baxter will accomplish its 50th anniversary in Germany. In the context of its celebration, what would you highlight as the main achievements of the company especially since you…
In the last twenty years, Germany has experienced nearly twenty health care reforms. In your opinion, what have been the main reasons for so many changes? The main reason behind…
Celgene is very new in the German market. What would you say have been the main achievements of Celgene Germany since its establishment in 2006? Celgene Germany started as a…
Could you briefly present the Association of German Biotechnology Companies (VBU) and DECHEMA e.V. to our readers and describe their importance to the German biotechnology industry? VBU is a non…
Hospira, which was spun-off from Abbott Laboratories in 2004, is a global specialty pharmaceutical and medication delivery company driven by its vision of Advancing Wellness™. Bringing proven leadership and experience,…
How challenging is for you as General Manager of Nycomed Germany to lead the number one subsidiary of the Nycomed Group and what would you highlight as the key milestones…
The acquisition of IVAX in 2006 was decisive to establish Teva as the number one generic producer worldwide and further consolidate the company in the German market; and this process…
Astellas has been present in the German market for almost two decades through Yamanouchi and Fujisawa. But since 2005 it gained a new identity thanks to the merger of the…
Cytonet is today Germany’s largest cell therapy enterprise. However, it went through many transformations since its spin-off from Roche Diagnostics in 2000. Could you briefly introduce the company to our…
The German Pharmaceutical Industry is not only known for its cutting-edge R&D and production base but also for having a high penetration of generics. In your opinion, what role do…
See our Cookie Privacy Policy Here